Abstract 14P
Background
C-Myc promoter binding protein (MBP-1) is a product of alternatively translated mRNA encoding alpha-enolase (ENO-1). In contrast to ENO-1, MBP-1 possesses no enzymatic activity but instead is able to bind P2 region of the c-Myc promoter leading to the modulation of its expression. Ectopic overexpression of MBP-1 was shown to reduce cell proliferation and tumorigenicity of numerous tumor cell lines, hence constituting an attractive target for cancer therapy.
Methods
We created lentiviral particles encoding HA-tagged, human MBP-1 protein, its C-terminal deletion mutant (MBP-1ΔC), or control, empty pRLL puro vector. With these tools, we created six stable transfectants derived from A375 and WM9 human melanoma cell lines. Detection of HA-tag by Western blot and immunofluorescence confirmed the overexpression of transfected proteins. We then used qPCR to estimate the effects of MBP-1 overexpression on the c-Myc transcription, Click-it Edu proliferation assay to assess the rate of cell proliferation, lactate detection assay in hypoxia and normoxia to measure the glycolytic rate and in vitro wound-healing assay to evaluate the migration ability of transduced cells.
Results
In our study, we found that overexpressed MBP-1 and MBP-1ΔC predominantly localized in the cytoplasm and only minimally decreased c-Myc mRNA expression, secondly, the proliferation rate of MBP-1- transduced cells increased in comparison to empty vector controls, and thirdly, the rate of glucose metabolism in normoxia and hypoxia increased in MBP-1 and MBP-1ΔC transduced cells. When assessing cell migration, we also found that overexpression of MBP-1 but not MBP-1ΔC led to a substantial decrease in the cell migration capacity of WM9 but not A375.
Conclusions
Our data underline potential pitfalls to avoid when overexpressing MBP-1 by means of lentiviral vectors. We provide evidence suggesting that lentiviral transduction of melanoma cell lines per se strongly affects cell proliferation and glucose metabolism. On the other hand, our research depicted an unexpected tumor-promoting activity of MBP-1 that can be largely dissociated from its nuclear localization and enzymatic activity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wroclaw Medical University, Wroclaw University of Environmental and Life Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
40P - Development of radiolabelled plerixafor as a theranostic molecule for targeting CXCR4 receptor expressing cancers: A translational study
Presenter: Tamanna Lakhanpal
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
Presenter: Beatriz Alonso de Castro
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Prognostic impact of the tumor immune microenvironment in adrenocortical cancer
Presenter: Nano Pachuashvili
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy
Presenter: Lauren Wood
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
Presenter: James Levin
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation
Presenter: Xiao Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Treatment management in RAS and BRAF mutations in patients with metastatic colorectal cancer
Presenter: Merve Özkan
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - KRAS mutation, the molecular landscape of lung adenocarcinoma in the Portuguese population
Presenter: Carolina Trabulo
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - Antitumor efficacy of polypyrrole-polyethyleneimine nanocomplex to target B-cell lymphoma
Presenter: Thi Thuy Nguyen
Session: Cocktail & Poster Display session
Resources:
Abstract